The addition of evolocumab to statin therapy provides a consistent and reliable low-density lipoprotein cholesterol (LDL-C) reduction in most patients, according to a recent secondary analysis of Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) trial data. In this placebo-controlled randomized clinical trial of the PCSK9 inhibitor evolocumab, researchers evaluated the percentage change in LDL-C levels from baseline in patients with stable atherosclerotic cardiovascular disease who were taking statin medications. Analyses in the patients were stratified by treatment arm. They found:
- 27,564 individuals were included in the cohort; 21,768 patients remained after exclusions for baseline variability or alterations in background lipid therapy and other causes.
- The addition of evolocumab to statin therapy lowered LDL-C levels by ≥50% in >90% of patients and by ≥30% in >99% of patients.
- Results were consistent across clinically relevant subgroups.
Qamar A, Giugliano RP, Keech AC, et al. Interindividual variation in low-density lipoprotein cholesterol level reduction with evolocumab: An analysis of FOURIER trial data. [Published online ahead of print December 12, 2018]. JAMA Cardiol. doi:10.1001/jamacardio.2018.4178.